Oncofetal chondroitin sulfate on tumor-derived extracellular vesicles: an emerging multivalent target for liquid biopsy
A placental protein reappearing on cancer particles in blood offers a new way to detect multiple cancer types from a simple blood test.
Oncofetal chondroitin sulfate (ofCS), normally placenta-restricted, is broadly re-expressed on tumor-derived extracellular vesicle surfaces across cancer types and detectable in pancreatic cancer patient plasma, offering a pan-cancer multivalent surface handle for tdEV-based liquid biopsy. This record was retained from the prior triage attempt for PubMed pipeline handoff.
What the study was
- Study design
- narrative_review
- Category
- Early Detection
- Maturity
- Validated
- Journal
- Biochim Biophys Acta Rev Cancer
Why it surfaced
ofCS addresses the fundamental unmet need in tdEV liquid biopsy—a cancer-restricted pan-cancer surface marker with patient specimen validation; pancreatic cancer early detection is one of the highest-impact clinical opportunities; directly informs liquid biopsy platform development strategy.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.